Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN)

I5Q-MC-CGAI -

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic migraine.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Migraines
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
1117
Trial Dates
Nov 30, 2015 - Jul 14, 2021
How long will I be in the trial?
Your participation could last up to 18 months and include 18 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have a diagnosis of chronic migraines, with a history of migraine headaches at least 1 year prior to screening for the study

  • Participant's migraines must have begun prior to age 50

Participants Must Not:

  • Participant must not have a history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine)

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.